KLRK1 and congenital rubella syndrome: No dose limiting toxicity (DLT), CRS or Immune effector cell-associated neurotoxicity syndrome (ICANS) was observed, none of the grade 3 and 4 adverse events were attributed to the NKG2D-CAR-T infusion.